Clinical trial details

A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer

Identifier

MK-3475A-D77

Sponsor

MERCK SHARP & DOHME CORP

Principal Investigator

ENRIQUETA FELIP FONT

Service

Oncology

Study details

Tumor type: LUNG-NSCLC
Stage: First Line/Previously Untreated
Main Investigational Agent : Immunotherapy
Phase: III
Randomization: Non-randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: Pembrolizumab + Platinum Doublet Chemotherapy
Arm B: Pembrolizumab coformulated with hyaluronidase + Platinum Doublet Chemotherapy

Links

Clinical Trials GOV (NCT identifier): NCT05722015
EU Clinical Trials Register (eudraCT Identifier): Not applicable